Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07578675
Recruiting Observational

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

NCT07578675 · tracked via the Priya Life Science China tracker
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Observational
Started
2025-10-11
Last updated
2026-09-18

Condition(s) studied

Aplastic AnemiaMyelodysplastic SyndromesAutoimmune Hemolytic AnemiaFunctional Near-Infrared Spectroscopy

Study summary

Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression.

Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of anemia * First hospitalization * Male or female, aged 18-65 years * Willing and able to comply with the requirements for this study and written informed consent Exclusion Criteria: * History of psychiatric illness * History of severe brain disease * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study

Primary outcome measure(s)

  • Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR) — Patients will be assessed within 48 hours of admission.
    Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.
  • Cognitive Function Assessment — Patients will be assessed within 48 hours of admission.
    Montreal Cognitive Assessment (MoCA) is used to assess cognitive function in patients, with higher total scores indicating better cognitive function. The total score range is 0 to 30.

Trial sites (1)

FacilityCityRegionStatus
Regenerative Medicine Center Tianjin Tianjin Municipality Recruiting

More Institute of Hematology & Blood Diseases Hospital, China trials in China

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Recruiting
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. Active, not recruiting
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model Recruiting
MRD-positive AML Clinical Study Recruiting
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT Recruiting

Other trials for the same condition

Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT Recruiting
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia Starting soon
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes Starting soon
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07578675 on ClinicalTrials.gov ↗ ← All trials in China